Introduction Older adults with type 2 diabetes (T2D) are at an increased risk of cardiovascular disease (CVD) compared with those without T2D.1 Although professional societies recommend the 2 classes of glucose-lowering agents, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), for their cardioprotective effects,2,3 adoption of these guidelines in routine care remains a challenge because evidence suggests that their cardiovascular benefits might not be uniform across patient subgroups. In particular, the protective effects of both SGLT2 inhibitors and GLP-1RAs on major adverse cardiovascular events (MACEs) were more substantial in patients with established atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF), whereas their effects on hospitalization for heart failure (HHF) did not differ by baseline CVD status.4,5 Age is also a potential modifier of the cardiovascular effects of SGLT2 inhibitors and GLP-1RAs; for example, empagliflozin, an SGLT2 inhibitor, was found to reduce the risk of cardiovascular death and MACEs only in patients older than 65 years,6,7 and liraglutide, the first agent in the GLP-1RA class to have reported cardioprotective benefits, reduced the risk of MACEs to a larger extent in patients older than 75 years compared with those younger than 75 years.8 Currently, limited evidence is available9 on the direct comparison of empagliflozin with liraglutide (or GLP-1RA class) in nonselected patients with a broader spectrum of ASCVD and/or HF risk and a higher mean age in routine clinical practice than those enrolled in clinical trials.10 This evidence across various subgroups of patients in routine care settings could help guide treatment decision-making by tailoring medications to those who will most benefit from them.